Our study evaluated the validity of the Nara declaration suggesting the use of serum ALT > 30 IU/L to identify metabolic dysfunction‐associated steatotic liver disease (MASLD) and further provided valuable evidence to validate the ability of fatty liver index and hepatic steatosis index to act as indices in identifying MASLD during health checkups. This evidence concerns the gene GPT and Hepatic steatosis.